Yüklüyor......

3′-Phosphoadenosine 5′-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents

Standard treatment for advanced non-small cell lung cancer (NSCLC) with no known driver mutation is platinum-based chemotherapy, which has a response rate of only 30–33%. Through an siRNA screen, 3′-phosphoadenosine 5′-phosphosulfate (PAPS) synthase 1 (PAPSS1), an enzyme that synthesizes the biologi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Leung, Ada W. Y., Dragowska, Wieslawa H., Ricaurte, Daniel, Kwok, Brian, Mathew, Veena, Roosendaal, Jeroen, Ahluwalia, Amith, Warburton, Corinna, Laskin, Janessa J., Stirling, Peter C., Qadir, Mohammed A., Bally, Marcel B.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2015
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4627299/
https://ncbi.nlm.nih.gov/pubmed/26220590
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!